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Double-Blind, Placebo-Controlled, Randomized Phase 2
Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in
Second-Line Non-small Cell Lung Cancer
Neal Ready, MD,* Nina A. Karaseva, MD,† Sergey V. Orlov, MD,‡ Alexander V. Luft, MD,§
Olexandr Popovych, MD, Jon T. Holmlund, MD,¶ Brian A. Wood, BS,¶ and Lance Leopold, MD¶
Background: AT-101 is an inhibitor of Bcl-2 family proteins
including Bcl-2, Bcl-xL, Mcl-1, and Bcl-w. In vivo and in vitro
studies have exhibited broad activity of AT-101, including synergy
with docetaxel in non-small cell lung cancer tumor models.
Methods: We conducted a prospective, randomized (1:1), double-
blind, placebo-controlled phase 2 study. Eligible patients must have
received one prior chemotherapeutic regimen for advanced or met-
astatic non-small cell lung cancer and may also have received
therapy with an epidermal growth factor receptor inhibitor. Patients
received AT-101 (40 mg b.i.d.  3 days) or placebo in combination
with docetaxel (75 mg/m2 on day 1) every 21 days. The primary
endpoint was progression-free survival (PFS) as determined by
independent review; other endpoints include overall survival and
PFS by investigator determination. Approximately 102 patients were
planned to provide 70 events (80% power, hazard ratio [HR] of 0.6,
one-sided alpha of 0.1).
Results: One hundred six patients were assigned to treatment and
105 patients received at least one dose of AT-101 or placebo.
Baseline factors were balanced between treatment groups: median
age 59 years; 77% men, and 79% current or former smokers.
Ninety-three percent of patients had distant metastatic disease at
randomization and 56% squamous histology. The most frequently
reported adverse events were fatigue (18%), anemia (18%), and
dyspnea (18%). No statistically significant differences in serious
adverse events were observed between AT-101 and placebo; grade
1/2 headaches appeared more frequently with AT-101 (9% versus
0%) and neutropenia was reported more frequently in the docetaxel
plus placebo arm compared with docetaxel plus AT-101 (17%
versus 8%). Unlike trials with continuous daily dosing of AT-101,
no cases of small bowel obstruction were reported. The response rate
and median PFS were not different between the arms by independent
review, PFS 7.5 weeks for docetaxel plus AT-101 and 7.1 weeks for
docetaxel plus placebo arms (HR, 1.04; p  0.57). The median
overall survival was 7.8 months for docetaxel plus AT-101 versus
5.9 months for docetaxel plus placebo (HR, 0.82; p  0.21).
Conclusions: The primary endpoint of improved PFS for AT-101
plus docetaxel was not met. AT-101 plus docetaxel was well
tolerated with an adverse event profile indistinguishable from the
base docetaxel regimen. AT-101 is the first oral, pan Bcl-2 family
inhibitor to exhibit a possible survival benefit in a randomized study.
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(J Thorac Oncol. 2011;6: 781–785)
Dysregulation of apoptosis is important to cancer pathogen-esis and has been associated with resistance to therapy. The
Bcl-2 family of proteins includes proapoptotic members (e.g.,
Bax, Bak, Bad, Bid, Bim, Noxa, Puma) and those that act to
suppress apoptosis (e.g., Bcl-2, Bcl-xL, Bcl-W, Mcl-1).1–3 An-
tiapoptotic Bcl-2 family members bind to the BH3 domains of
proapoptotic family members, sequestering them and thereby
inhibiting their ability to promote apoptotic cell death. Overex-
pression of the protein products of some Bcl-2 genes has been
reported to correlate with adverse prognosis and resistance to
therapy in certain malignancies.4
Peptide and nonpeptide BH3 mimetics have been shown
in laboratory studies to inhibit the heterodimerization of Bcl-2 or
Bcl-xL to proapoptotic BH3 family members with the attendant
expected effects of increasing mitochondrial permeability and
cytochrome c release, activation of caspases, and apoptosis.5
AT-101 is a BH3 mimetic that inhibits the heterodimerization of
Bcl-2, Bcl-xL, Bcl-W, and Mcl-1 with proapoptotic members of
the Bcl-2 family at submicromolar affinity (Investigator’s Bro-
chure, 2006). AT-101 [R-(-)-gossypol acetic acid] is the levoro-
tatory enantiomer of gossypol. AT-101 is a BH3 mimetic that
lowers the threshold for apoptosis by inhibiting the het-
erodimerization of Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 with pro-
apoptotic Bcl-2 proteins. More recent studies have also indicated
that AT-101 treatment results in potent induction of the natural
ligands of Mcl-1, Bcl-2, and Bcl-xL, Noxa and Puma, which are
proapoptotic, as well as inhibiting angiogenesis.6,7 In vivo and in
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vitro studies have exhibited broad activity of AT-101 in a
number of different preclinical tumor models. Preclinical studies
indicate that there is additive or synergistic activity from the
combination of docetaxel and AT-101 in prostate and lung
cancer models (unpublished results).
Phase I clinical trial data show that the most common
adverse events for AT-101 on a once daily for 21 of 28-day
schedule have been gastrointestinal and grade 1/2 fatigue.
The gastrointestinal adverse events included nausea, vomiting,
abdominal pain, abdominal discomfort, diarrhea, constipation,
and nonmechanical small bowel obstruction (SBO). The most
common serious adverse events reported include nausea, vom-
iting, and SBO, especially after several months of continuous
dosing. With intermittent dosing of higher doses of AT-101 on
3 days every 21 days, there are fewer gastrointestinal adverse
events than with continuous dosing of AT-101. Phase I trials
combining docetaxel day 1 every 21 days with AT-101 40 mg
twice daily days 1 to 3 had no apparent increased toxicity
compared with chemotherapy alone.8
Docetaxel has been shown to be effective in previously
treated non-small cell lung cancer (NSCLC).9–11 The disease
ultimately becomes resistant to docetaxel, and increased ex-
pression of bcl-2 family proteins is one of the possible
resistance mechanisms in that setting. This randomized, pla-
cebo controlled trial compares docetaxel with or without
AT-101 in previously treated NSCLC.
METHODS
Eligible patients had histologic documentation of NSCLC.
All patients had advanced disease, malignant pleural/pericardial
effusion, distant metastatic disease, or recurrent NSCLC inap-
propriate for definitive local therapy. Eligibility criteria in-
cluded Eastern Cooperative Oncology Group performance
status (PS) of 0 to 2, standard initial laboratory tests, and
relapse after one previous chemotherapeutic regimen in lo-
cally advanced, or metastatic disease; or recurrent disease
less than 6 months after adjuvant chemotherapy for resected
early-stage lung cancer. Subjects with treated, central nervous
system metastases were eligible, if the patient was neurolog-
ically stable and did not require steroid therapy at study entry.
The trial was amended to exclude PS 2 patients after it was
determined that PS 2 patients were overrepresented in the
initial enrollment cohort. In addition to one prior chemother-
apeutic regimen, patients may have received erlotinib or
another epidermal growth factor inhibitor in any setting. Each
participant signed an institutional review board approved,
protocol-specific informed consent in accordance with na-
tional and institutional guidelines. Registration and data col-
lection were managed by a central data management system.
Treatment Plan
After patients were registered and stratified by PS (0 or
1 versus 2) and time since last chemotherapy (3 months versus
3 months), they were randomized 1:1 to receive docetaxel 75
mg/m2 day 1 with AT-101 40 mg twice daily days 1 to 3 every
21 days or the same docetaxel regimen with placebo. Dexa-
methasone 8 mg oral twice daily days 1, 1, and 2, and
antiemetics were allowed. Patients were to receive a maxi-
mum of 10 cycles of therapy unless unacceptable toxicity or
disease progression occurred. Radiologic and response as-
sessment with computed tomography scan or magnetic reso-
nance imaging of chest/abdomen were obtained at day 1 of
cycles 3, 5, 7, and 9, or at symptomatic progression.
Dose Modifications
Dose delays and modifications of docetaxel and AT-
101/placebo were made, as necessary, because of treatment-
related toxicity. Treatment with AT-101/placebo and do-
cetaxel was delayed, up to 2 weeks (14 days), to allow for
resolution of toxicity. If a single dose reduction of AT-101/
placebo was required, the reduced dose was 30 mg twice a
day on cycle days 1 to 3. If a second dose reduction of
AT-101/placebo was required, the dose was 20 mg twice a
day on cycle days 1 to 3. The dose of docetaxel was reduced
by 15 mg/m2 for each dose reduction. Unacceptable toxicity
was defined as toxicity requiring more than two dose reduc-
tions, persistent toxicity requiring a delay of therapy for more
than 2 weeks (14 days), a severe hypersensitivity reaction
(i.e., hypotension, bronchospasm, and/or generalized rash/
erythema) to AT-101/placebo or docetaxel, or  grade 3
peripheral neuropathy.
Measurements
RECIST was used to define complete response (CR),
partial response (PR), stable disease (SD), and progressive
disease (PD).12 The overall response rate for the two arms
was compared by Fisher exact test with confidence intervals
(CI). Survival was defined as the time from randomization
until death as a result of any cause. For patients who do not
die, time to death was censored at the time of last contact.
Overall survival (OS) was summarized using Kaplan-Meier
survival curves and compared between treatment arms using
a stratified log-rank test, with a one-sided alpha of 0.1. An
estimate of the hazard ratio (HR) with 95% CI was also
calculated.
Statistical Consideration
A total of 102 patients were planned to be enrolled in
this double-blind, placebo-controlled, two-arm, randomized
study. A 1:1 randomization scheme was used, resulting in
approximately 51 patients assigned to receive docetaxel plus
AT-101, and approximately 51 patients assigned to receive
docetaxel plus placebo. Patient randomization was stratified
by Eastern Cooperative Oncology Group PS (0 or 1 versus 2)
and time since last chemotherapy (3 months versus 3
months). Independent radiographic review was used to deter-
mine response and time of progression, in accordance with
RECIST criteria.
Sample Size Estimates
The primary efficacy analysis is a stratified log-rank
test of the progression-free survival (PFS) endpoint to com-
pare patients receiving AT-101  docetaxel (arm A) versus
those receiving docetaxel  placebo (arm B). The number of
events required for this study was computed using the fol-
lowing specifications: proportional hazards, one-sided type I
error probability of 0.10, power of 80%, and an HR (inves-
tigational: control) of 0.60. These specifications lead to a
requirement of 70 progression or death events.
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The number of patients required was projected using
simulation to be 102 by specifying a control arm median PFS
time of 3 months, exponential PFS distributions, 9 months of
accrual including a 3-month linear ramp-up time, and 3
months of follow-up after accrual of the last patient until the
required number of events realization time.
Analysis Sets
The modified Intent-to-Treat (ITT) analysis set comprised
all randomized patients who received at least one dose of
AT-101/placebo and/or docetaxel and was used for the analysis
of efficacy data. The deletion of patients not receiving study
drug has the same validity as an ITT analysis provided there is
no bias regarding who gets the first treatment in this double-
blind study. The Safety analysis set comprised all randomized
patients who receive at least one dose of AT-101/placebo and/or
docetaxel and was based on the actual treatment received if this
differs from that to which the subject was randomized. The
primary efficacy analysis of PFS was based on the modified ITT
patient population and used the independent assessment of
response or date of progression where applicable. PFS is the
number of days between the date of randomization and the
earliest date of disease progression or death from any cause.
Patients without disease progression or death were censored at
the time of initiation of alternative anticancer therapy or last
contact. The date of progression used was determined by the
independent assessor. Treatment arms were compared using a
stratified log-rank test. An estimate of the treatment HR is based
on proportional hazard regression and was given, together with
a 95% CI.
RESULTS
Between October 2007 and August 2008, a total of 117
patients provided informed consent and were screened for
this study at 19 centers located in the United States and
Russia. One hundred six patients were deemed eligible and
randomized, 54 AT-101 and 52 placebo. The two arms of the
study were well balanced for demographics (Table 1). The
patient population had a mean age of about 59 years, and 87%
of the patients were men. About 80% of patients had received
one prior chemotherapeutic regimen for lung cancer. Eighty-
three percent (83%), of patients in the AT-101 plus docetaxel
arm had a PS of 0 or 1 versus 87% in the placebo plus
docetaxel arm. In this study, 25% of patients in the AT-101
plus docetaxel arm and 17% of patients in the docetaxel plus
placebo arm were defined as a never smoker. The majority of
patients had squamous cell histology, 53% versus 60% in the
AT-101 plus docetaxel and placebo plus docetaxel arms, respec-
tively. There was no imbalance between the arms in poor
prognostic characteristics such as liver metastases. On both
arms, there was a high rate of primary chemotherapy resistance
to frontline chemotherapy with 43% of patients having PD as
best response to initial therapy. One patient on the AT-101 arm
developed a headache immediately before initiation of clinical
trial therapy, and brain imaging showed possible progression of
previously treated brain metastases. This patient was deemed
ineligible, received no protocol therapy, and was not included in
analysis as defined in the protocol.
The toxicities experienced on this trial were typical of
those reported for second-line docetaxel in this setting (Table 2).
There was no increase in grade 3 or higher toxicities for the
AT-101 arm compared with placebo. Grade 1 or 2 headache was
the only toxicity that was significantly increased in the AT-101
arm compared with placebo. Patients on the AT-101 plus do-
cetaxel arm and placebo plus docetaxel arm received a median
of 3 cycles and 2 cycles of treatment, respectively. The results
were negative for the primary endpoint of improving PFS for
AT-101 plus docetaxel compared with placebo plus docetaxel
with PFS of 7.5 weeks for both arms (Figure 1). The HR for PFS
was 0.93 (95% CI: 0.2–4.3).
This study used an independent review of radiographic
data to determine RECIST status. There was also no signif-
TABLE 1. Demographic Data for Enrolled Patients
Docetaxel  AT-101 Docetaxel  Placebo
N  53 N  52
Median age, yr 58 59.5
65, % 38 29
Female, N (%) 11 (21) 13 (25)
Never smokers, N (%) 13 (25) 9 (17)
Median time since last
chemotherapy, mo
2.8 3.2
Prior surgery, N (%) 16 (30) 22 (42)
RT, N (%) 12 (23) 17 (33)
Median time since
diagnosis, mo
9.1 8.6
Histology, N (%)
Squamous 28 (53) 31 (60)
Adenocarcinoma 18 (34) 14 (27)
Large cell 2 (4) 5 (10)
BAC 3 (6) 1 (2)
NOS 2 (4) 1 (2)
Stage at diagnosis, %
1/2/3a/3b/4
4/8/8/25/57 4/8/14/27/48
Stage at baseline 3b/4,
N (%)
4 (8)/49 (93) 2 (4)/50 (96)
ECOG PS, N (%)
0 3 (6) 6 (12)
1 41 (77) 39 (75)
2 9 (17) 7 (14)
No. metastatic sites,
N (%)
0 3 (6) 4 (8)
1 24 (45) 23 (44)
2 23 (43) 18 (35)
3 3 (6) 7 (13)
Prior # regimens, N (%)
1 44 (83) 41 (79)
2 8 (15) 11 (21)
2 1 (2) 0
Prior platinum, % 53 (100) 49 (94)
EGFR inhibitor, N (%) 9 (17) 9 (17)
There were no significant imbalances.
RT, radiotherapy; BAC, bronchoalveolar carcinoma; NOS, not otherwise specified;
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal
growth factor receptor.
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icant improvement in response rate for AT-101 compared
with placebo). In the placebo plus docetaxel arm, there were
no CRs, one (2.1%) PR, and 22 (46.8%) patients with SD for
an overall disease control rate of 48.9%. In the AT-101 plus
docetaxel arm, there were no CRs, two (4.3%) PRs, and 22
(47.8%) patients with SD for an overall disease control rate of
52.2%.
At the protocol specified data analysis time point, there
was an increase in OS of 1.9 months for docetaxel plus
AT-101 compared with docetaxel plus placebo (Figure 2).
The HR was 0.82 (95% CI: 0.5–1.3), and it was not statisti-
cally significant (log rank p  0.21, wilcoxon p  0.13). On
longer follow-up, the 1.9-month OS benefit was unchanged.
There was no apparent difference for improved survival for
AT-101 compared with placebo based on histology; squa-
mous cell HR 0.74 compared with adenocarcinoma HR 0.67
histology. The difference in survival outcome was also not
explained by more patients on the AT-101 arm receiving
subsequent anticancer therapy with 12 and 14 patients receiv-
ing subsequent anticancer therapy on the AT-101 and placebo
arms, respectively. Six patients crossed over from placebo to
receive AT-101; no responses were observed in the crossover
patients.
Posttrial therapy was not standardized. On the placebo
arm, 14 patients are reported to have received at least one
additional therapy, and some of these therapies were 4 cis-
platin, 4 etoposide, 4 gemcitabine, 3 carboplatin, 3 paclitaxel,
2 cyclophosphamide, and 1 erlotinib. On the AT-101 arm, 12
patients are reported to have received at least one additional
therapy, and these therapies were 4 cisplatin, 4 gemcitabine,
3 carboplatin, 3 paclitaxel, 2 vincristine, 2 etoposide, 1
erlotinib, and 1 pemetrexed.
DISCUSSION
The combination of docetaxel and AT-101 was well
tolerated. There was no increase for grade 3 and 4 toxicity for
AT-101 compared with placebo. The only increase in toxicity
for the AT-101 arm compared with placebo was grades 1 and
2 headache. Phase I trials studying continuous dosing of
AT-101 reported nausea, abdominal discomfort, and nonme-
chanical SBO. In this trial and other trials studying AT-101
twice daily therapy for 3 days every 3 weeks, there is no
increase in abdominal toxicity, bone marrow toxicity, infec-
tions, or other serious side effects.8
This was a negative trial for the primary endpoint of
improving PFS for docetaxel plus AT-101 compared with
AT-101 plus placebo. There was also no improvement in
response rate for the AT-101 arm compared with placebo.
Median OS was numerically superior by 1.9 months for
docetaxel and AT-101 compared with docetaxel plus placebo
but did not reach statistical significance (HR, 0.82; log rank,
p  0.21).
Compared with other trials studying single agent do-
cetaxel in previously treated NSCLC, most outcomes on this
trial were inferior.9–11 PFS for both arms on this trial was
about 7.5 weeks, whereas PFS on the other trials ranged from
8.5 to 11.6 weeks. Similarly, the OS for the docetaxel control
arm on this trial was 5.9 months, whereas the OS on the
Shepherd trial was 7.5 months and the Hanna trial was 7.9
months. One possible contributing factor to the inferior sur-
vival on this trial was that squamous cell was the most
common histology (Table 1). These results may also be
TABLE 2. Toxicity Data for Treated Patients
Docetaxel  AT-101
(N  53)
Docetaxel  PBO
(N  52)
Grade 1/2 Grade 3/4/5 Grade 1/2 Grade 3/4/5
N (%) N (%) N (%) N (%)
Any adverse event 24 (45.3) 23 (43.4) 14 (26.9) 32 (61.5)
Fatigue 6 (11.3) 2 (3.8) 8 (15.4) 4 (7.7)
Asthenia 5 (9.4) 2 (3.8) 4 (7.7) 2 (3.8)
Disease
progression
0 (0) 2 (3.8) 0 (0) 8 (15.4)
Dyspnea 7 (13.2) 3 (5.7) 9 (17.3) 1 (1.9)
Anemia 7 (13.2) 3 (5.7) 10 (19.2) 0 (0)
Neutropenia 1 (1.9) 5 (9.4) 2 (3.8) 7 (13.5)
Leukopenia 0 (0) 2 (3.8) 1 (1.9) 3 (5.8)
Hyperglycemia 4 (7.5) 1 (1.9) 2 (3.8) 3 (5.8)
Hypermagnesemia 0 (0) 1 (1.9) 0 (0) 4 (7.7)
EKG QT
prolonged
5 (9.4) 1 (1.9) 6 (11.5) 1 (1.9)
Nausea 8 (15.1) 1 (1.9) 8 (15.4) 0 (0)
Headache 6 (11.3) 0 (0) 0 (0) 0 (0)
Only grades 1 and 2 headache were increased for docetaxel and AT-101.
EKG, electrocardiogram.
FIGURE 1. Independently assessed progression-free survival
(PFS) was no different between the treatment arms.
FIGURE 2. Kaplan-Meier Overall Survival Curve (Modified
Intent-to-Treat [ITT] Population) was greater on the do-
cetaxel and AT-101 arm compared with the placebo arm
(hazard ratio [HR], 0.82), but the difference was not statisti-
cally significant (p  0.21).
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explained by the possibility that the patients on this trial had
more chemotherapy resistant tumors compared with other
trials in this setting. PD was the best response to first-line
therapy in 43% of tumors in this trial, whereas PD as best
response ranged from 18 to 31% in the docetaxel arms of
three randomized trials.9–11
It is possible that the improvement in survival for the
AT-101 arm was due to the small sample size and is not a
signal of activity for the combination of AT-101 and do-
cetaxel. The AT-101 arm had more nonsmokers 13 (25%)
compared with the placebo arm 9 (17%), and the number of
patients receiving epidermal growth factor receptor tyrosine
kinase inhibitor therapy before or poststudy was equal at nine
(17%) and one (2%), respectively, in both arms. Neither of
these factors appears to account for the observed difference in
the OS. It is also possible that there is a modest improvement
in survival for the addition of AT-101 to docetaxel in the
setting of previously treated NSCLC, but the sample size was
underpowered to validate a statistically significant difference
in survival. A survival difference could exist when no differ-
ence in PFS was detected, because progression documented
by scheduled restaging computed tomography scan may not
accurately document the actual time of progression. This
factor is significant in settings such as previously treated
NSCLC in which PFS times are short relative to the sched-
uled testing interval of every 6 weeks. Response rates for
docetaxel in second-line therapy for NSCLC are less than
10%, so one would not expect to be able to accurately detect
a modest improvement in response rate in a 100-patient
clinical trial. It is also possible that survival could be pro-
longed with a proapoptotic agent such as AT-101 through
mechanisms that do not result in an increase in objective
tumor shrinkage.
NSCLC is a heterogeneous group of malignancies in
regard to prognosis and response to cytotoxic or molecular
therapy. Many molecular targeted therapies may be effective
in subpopulations of NSCLC but not have enough activity to
warrant development in unselected NSCLC. Preclinical stud-
ies using gene expression analysis of lung cancer cell lines
exposed to AT-101 may identify a biomarker for AT-101 in
NSCLC that could guide future clinical trials.13–15 The iden-
tification of a gene expression based biomarker for AT-101
could provide the opportunity to design clinical trials for a
subset of NSCLC most likely to benefit from AT-101.
In conclusion, the combination of docetaxel and AT-101
was very well tolerated. The trial did not meet the primary
endpoint for improved PFS. The experimental AT-101 arm had
a numerically superior survival outcome compared with pla-
cebo. The survival difference between the arms may have been
because of random chance from a small sample size or an
imbalance in prognostic factors. Alternatively, this small numer-
ical improvement in OS may indicate efficacy for the combina-
tion of docetaxel and AT-101 compared with docetaxel alone in
previously treated NSCLC.
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